Presentation at Bio Contact Québec 2007



    HAE:TSX

    MONTREAL, Oct. 2 /CNW Telbec/ - Haemacure Corporation (TSX:HAE), a
specialty bio-therapeutics company developing high-value human proteins,
announces that Mr. Joseph Galli, Chairman and Chief Executive Officer, will be
presenting at BioContact Québec 2007. Mr. Galli will be speaking on Wednesday,
October 3, 2007 at 16:30 in the Bellevue Room, Chateau Frontenac in Québec
City.

    About BioContact Québec 2007

    BioContact Québec 2007 (www.biocontact.qc.ca) is a biopharmaceutical
partnership symposium gathering over 1200 participants. More than
150 biopharmaceutical companies, coming from Canada, the United States, Asia
and Europe, will be presenting in different sectors of activities
(diagnostics, therapeutics and services) and disciplines such as cancer,
cardiology, drug delivery systems, endocrinology, genomics/proteomics,
immunology/infectiology, neurobiology, virology and medical technologies.

    About Haemacure

    Haemacure Corporation is a specialty bio-therapeutics company developing
high-value human therapeutic proteins for commercialization. Haemacure's
research and development effort is driven by its proprietary plasma protein
extraction technology to develop next-generation products, including surgical
hemostats.
    Haemacure's lead product candidate, Hemaseel(TM)HMN, is a human-derived
fibrin sealant in late-stage clinical development. Haemacure's second product
candidate is human thrombin, a component of its fibrin sealant. Both
candidates have applications in the expanding bio-surgical market. Follow-on
development will focus on surgical hemostats, biomaterial combinations and
drug delivery in select therapeutic areas. Haemacure has recently discovered
additional specialty proteins in its plasma-derived intermediates and will
advance these specialty proteins through partnerships with other
pharmaceutical and biotechnology companies.

    Forward-looking Statements

    Certain statements contained in this news release and oral statements
made by representatives of Haemacure that are not historical facts may be
considered forward-looking statements. Such statements, based as they are on
the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
Corporation does business, stock market volatility, fluctuations in costs, the
ability of Haemacure to set up its planned manufacturing facility, the
completion and outcome of clinical studies as well as the development of new
products, and changes to the competitive environment due to consolidation or
otherwise. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. Haemacure
Corporation disclaims any intention or obligation to update these statements.




For further information:

For further information: Joseph Galli, Chairman and CEO, Haemacure
Corporation, (514) 990-7074, jgalli@pentor.com; IR Contact: Gilles Lemieux,
Haemacure Corporation, (514) 282-3350 ext. 22, glemieux@haemacure.ca

Organization Profile

HAEMACURE CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890